NEW YORK, Oct. 8 — Ciphergen Biosystems and Pfizer said on Monday that they would collaborate on a predictive toxicology study using Ciphergen’s ProteinChip system and arrays. The study will aim to discover proteins in serum from rat models and to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. Financial and other terms of the agreement were not disclosed.